Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14000509 | 0.87 | RECQL (0.65) | RECQLKMOALDH1A1PLA2G10 | |
| SCHEMBL5430669 | 0.86 | RECQL (0.84) | RECQLKMOHSD17B10ALDH1A1 | |
| SCHEMBL248214 | 0.84 | RECQL (1.00) | RECQLKMOHSD17B10ALDH1A1 | |
| SCHEMBL30346162 | 0.84 | RECQL (1.00) | RECQLKMOHSD17B10ALDH1A1 | |
| SCHEMBL25412409 | 0.84 | RECQL (0.60) | RECQLKMOHCAR3KDM4EALDH1A1 | |
| SCHEMBL30614221 | 0.84 | RECQL (0.60) | RECQLKMOHCAR3KDM4EALDH1A1 | |
| SCHEMBL28312593 | 0.84 | RECQL (0.60) | RECQLKMOHCAR3KDM4EALDH1A1 | |
| SCHEMBL3724300 | 0.83 | RECQL (0.60) | RECQLKMOALDH1A1DRD2TBXA2R | |
| SCHEMBL8366923 | 0.83 | RECQL (0.60) | RECQLKMO | |
| SCHEMBL30614225 | 0.82 | RECQL (0.51) | RECQLKMOHCAR3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778838-A | Azacyclylbenzamide derivatives as histamine-3 antagonists | WYETH CORP | 2010-07-14 | — | — | CN | disclosed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | RECQL 2703/4885KMO 502/4885PTGER4 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.